Literature DB >> 25609808

Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody.

Ki Joon Cho1, Bert Schepens2, Jong Hyeon Seok3, Sella Kim3, Kenny Roose2, Ji-Hye Lee3, Rodrigo Gallardo4, Evelien Van Hamme2, Joost Schymkowitz4, Frederic Rousseau4, Walter Fiers2, Xavier Saelens5, Kyung Hyun Kim6.   

Abstract

UNLABELLED: The extracellular domain of influenza A virus matrix protein 2 (M2e) is conserved and is being evaluated as a quasiuniversal influenza A vaccine candidate. We describe the crystal structure at 1.6 Å resolution of M2e in complex with the Fab fragment of an M2e-specific monoclonal antibody that protects against influenza A virus challenge. This antibody binds M2 expressed on the surfaces of cells infected with influenza A virus. Five out of six complementary determining regions interact with M2e, and three highly conserved M2e residues are critical for this interaction. In this complex, M2e adopts a compact U-shaped conformation stabilized in the center by the highly conserved tryptophan residue in M2e. This is the first description of the three-dimensional structure of M2e. IMPORTANCE: M2e of influenza A is under investigation as a universal influenza A vaccine, but its three-dimensional structure is unknown. We describe the structure of M2e stabilized with an M2e-specific monoclonal antibody that recognizes natural M2. We found that the conserved tryptophan is positioned in the center of the U-shaped structure of M2e and stabilizes its conformation. The structure also explains why previously reported in vivo escape viruses, selected with a similar monoclonal antibody, carried proline residue substitutions at position 10 in M2.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25609808      PMCID: PMC4403401          DOI: 10.1128/JVI.02576-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Conformational analysis of the full-length M2 protein of the influenza A virus using solid-state NMR.

Authors:  Shu Yu Liao; Keith J Fritzsching; Mei Hong
Journal:  Protein Sci       Date:  2013-10-07       Impact factor: 6.725

2.  A graphical interface for the FoldX forcefield.

Authors:  Joost Van Durme; Javier Delgado; Francois Stricher; Luis Serrano; Joost Schymkowitz; Frederic Rousseau
Journal:  Bioinformatics       Date:  2011-04-19       Impact factor: 6.937

3.  Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Authors:  Andres G Grandea; Ole A Olsen; Thomas C Cox; Mark Renshaw; Philip W Hammond; Po-Ying Chan-Hui; Jennifer L Mitcham; Witold Cieplak; Shaun M Stewart; Michael L Grantham; Andrew Pekosz; Maki Kiso; Kyoko Shinya; Masato Hatta; Yoshihiro Kawaoka; Matthew Moyle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-01       Impact factor: 11.205

4.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

5.  Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel.

Authors:  Rafal M Pielak; James J Chou
Journal:  Biochem Biophys Res Commun       Date:  2010-09-15       Impact factor: 3.575

6.  Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly.

Authors:  Judith Verhelst; Eef Parthoens; Bert Schepens; Walter Fiers; Xavier Saelens
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

7.  Structural basis of respiratory syncytial virus neutralization by motavizumab.

Authors:  Jason S McLellan; Man Chen; Albert Kim; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2010-01-24       Impact factor: 15.369

8.  Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.

Authors:  Eleanor L Ramos; Jennifer L Mitcham; Teri D Koller; Aurelio Bonavia; Dale W Usner; Ganesh Balaratnam; Paul Fredlund; Kristine M Swiderek
Journal:  J Infect Dis       Date:  2014-10-03       Impact factor: 5.226

9.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

10.  The molecular basis of the specific anti-influenza action of amantadine.

Authors:  A J Hay; A J Wolstenholme; J J Skehel; M H Smith
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

View more
  27 in total

1.  Crystal Structure of the Conserved Amino Terminus of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus Gripped by an Antibody.

Authors:  Ki Joon Cho; Bert Schepens; Kristof Moonens; Lei Deng; Walter Fiers; Han Remaut; Xavier Saelens
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

3.  Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.

Authors:  Silvie Van den Hoecke; Katrin Ehrhardt; Annasaheb Kolpe; Karim El Bakkouri; Lei Deng; Hendrik Grootaert; Steve Schoonooghe; Anouk Smet; Mostafa Bentahir; Kenny Roose; Michael Schotsaert; Bert Schepens; Nico Callewaert; Falk Nimmerjahn; Peter Staeheli; Hartmut Hengel; Xavier Saelens
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

4.  Mx1 in Hematopoietic Cells Protects against Thogoto Virus Infection.

Authors:  Jan Spitaels; Lien Van Hoecke; Kenny Roose; Georg Kochs; Xavier Saelens
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

5.  The Influenza M2 Ectodomain Regulates the Conformational Equilibria of the Transmembrane Proton Channel: Insights from Solid-State Nuclear Magnetic Resonance.

Authors:  Byungsu Kwon; Mei Hong
Journal:  Biochemistry       Date:  2016-09-12       Impact factor: 3.162

6.  Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity in vivo.

Authors:  Sweety Samal; Tripti Shrivastava; Praveen Sonkusre; Zaigham Abbas Rizvi; Rajesh Kumar; Shubbir Ahmed; Preeti Vishwakarma; Naveen Yadav; Manish Bansal; Kanchana Chauhan; Sebanta Pokhrel; Supratik Das; Padmakar Tambare; Amit Awasthi
Journal:  J Biol Chem       Date:  2020-08-13       Impact factor: 5.157

7.  Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2.

Authors:  Peiyang Ding; Qianyue Jin; Xinxin Chen; Suzhen Yang; Junqing Guo; Guangxu Xing; Ruiguang Deng; Aiping Wang; Gaiping Zhang
Journal:  Int J Nanomedicine       Date:  2019-09-16

8.  Viral dosing of influenza A infection reveals involvement of RIPK3 and FADD, but not MLKL.

Authors:  Teodora Oltean; Emily Van San; Tatyana Divert; Tom Vanden Berghe; Xavier Saelens; Jonathan Maelfait; Nozomi Takahashi; Peter Vandenabeele
Journal:  Cell Death Dis       Date:  2021-05-11       Impact factor: 8.469

9.  Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.

Authors:  Lynn Bimler; Sydney L Ronzulli; Amber Y Song; Scott K Johnson; Cheryl A Jones; Teha Kim; Duy T Le; S Mark Tompkins; Silke Paust
Journal:  J Virol       Date:  2020-12-02       Impact factor: 6.549

10.  Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.

Authors:  Umesh Kalathiya; Monikaben Padariya; Robin Fahraeus; Soumyananda Chakraborti; Ted R Hupp
Journal:  Biomolecules       Date:  2021-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.